Dopamine Partial Agonists

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy

2016 • 8,701 citations

Dopamine Receptors: From Structure to Function

1998 • 3,489 citations

Antipsychotic-Induced Weight Gain: A Comprehensive Research Synthesis

1999 • 2,382 citations

Effect of Chlorpromazine or Haloperidol on Formation of 3‐Methoxytyramine and Normetanephrine in Mouse Brain

1963 • 2,148 citations

Dopamine in schizophrenia: a review and reconceptualization

1991 • 1,963 citations

The neuropathology of schizophrenia

1999 • 1,664 citations

Antipsychotic drug doses and neuroleptic/dopamine receptors

1976 • 1,623 citations

Neuropsychopharmacology

1990 • 1,545 citations

Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia

2003 • 1,160 citations

GABAergic Interneurons Implications for Understanding Schizophrenia and Bipolar Disorder

2001 • 1,080 citations

Positron Emission Tomography Reveals Elevated D ₂ Dopamine Receptors in Drug-Naive Schizophrenics

1986 • 935 citations

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

2003 • 918 citations

The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia

2001 • 915 citations

Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors

2002 • 896 citations

Atypical Antipsychotics: Mechanism of Action

2002 • 892 citations

Molecular Characterization of Schizophrenia Viewed by Microarray Analysis of Gene Expression in Prefrontal Cortex

2000 • 884 citations

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

1999 • 807 citations

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET

1997 • 707 citations

The Role of Serotonin in Antipsychotic Drug Action

1999 • 672 citations

Dopamine D4 receptors elevated in schizophrenia

1993 • 632 citations

Efficacy and Safety of Aripiprazole and Haloperidol Versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder

2002 • 624 citations

Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder

2003 • 591 citations

Provocative tests with psychostimulant drugs in schizophrenia

1987 • 535 citations

D2 Dopamine Receptors in Neuroleptic-Naive Schizophrenic Patients

1990 • 526 citations

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

2002 • 506 citations

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

2003 • 472 citations

Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies

1999 • 452 citations

Bringing Order to the Glutamate Chaos in Schizophrenia

2003 • 412 citations

Interactions of the Novel Antipsychotic Aripiprazole (OPC-14597) with Dopamine and Serotonin Receptor Subtypes

1999 • 407 citations

Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient

2001 • 377 citations

Essential Psychopharmacology: Neuroscientific Basis and Practical Applications

1996 • 374 citations

Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

1997 • 358 citations

Control of Serotonergic Function in Medial Prefrontal Cortex by Serotonin-2A Receptors through a Glutamate-Dependent Mechanism

2001 • 317 citations

Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia

2003 • 310 citations

Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia

2003 • 308 citations

Dopamine receptors and transporters in Parkinson's disease and schizophrenia

1990 • 302 citations

Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]Raclopride

2002 • 299 citations

Improving the treatment of schizophrenia: focus on serotonin (5-HT)(1A) receptors.

2000 • 290 citations

Imaging dopamine transmission in schizophrenia. A review and meta-analysis.

1998 • 281 citations

PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride

1987 • 279 citations

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

1995 • 268 citations

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

2003 • 252 citations

Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia

1999 • 249 citations

Treatment of Negative Symptoms in Schizophrenia with Amisulpride

1995 • 219 citations

Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.

1997 • 215 citations

Serotonergic basis of antipsychotic drug effects in schizophrenia

1998 • 206 citations

Epidemiology, morbidity, and treatment of overweight and obesity.

2001 • 182 citations

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia

1999 • 173 citations

An integrated view of pathophysiological models of schizophrenia

1999 • 173 citations

Localization of 5-HT2A receptors on dopamine cells in subnuclei of the midbrain A10 cell group

2002 • 169 citations

Neuroleptic-induced hyperprolactinemia

1999 • 150 citations

Partial dopamine agonists in the treatment of psychosis

2002 • 147 citations

Do classical hallucinogens act as 5-HT2 agonists or antagonists?

1990 • 137 citations

Binding of Antipsychotic Drugs to Cortical 5-HT_2A Receptors: A PET Study of Chlorpromazine, Clozapine, and Amisulpride in Schizophrenic Patients

1998 • 125 citations

Antipsychotic Properties of the Partial Dopamine Agonist (−)-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia

1998 • 107 citations

Aripiprazole, a novel antipsychotic drug, inhibits quinpriole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum

1997 • 101 citations

m-Chlorophenylpiperazine Effects in Neuroleptic-Free Schizophrenic Patients

1993 • 99 citations

Linkage analysis of schizophrenia with five dopamine receptor genes in nine pedigrees.

1993 • 98 citations

Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia

1999 • 91 citations

Effects of the novel antipsychotic agent 7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro -2(1H)-quinolinone (OPC-14597) on prolactin release from the rat anterior pituitary gland.

1996 • 90 citations

GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses

1999 • 90 citations

The dopamine hypothesis of schizophrenia

1997 • 88 citations

Dopamine agonists in schizophrenia: a review

1995 • 59 citations

Serotonin function in schizophrenia: Effects of meta- chlorophenylpiperazine in schizophrenia patients and healthy subjects

1992 • 49 citations

P.2.114 Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result

1997 • 33 citations

The Behavioral Effect of m-Chlorophenylpiperazine (mCPP) and Methylphenidate in First-Episode Schizophrenia and Normal Controls

1997 • 30 citations

Strategy for Modulation of Central Dopamine Transmission Based on the Partial Agonist Concept in Schizophrenia Therapy

2001 • 30 citations

Clozapine attenuates meta-chlorophenylpiperazine (mCPP)-induced plasma cortisol increases in schizophrenia

1993 • 26 citations

DU 127090: a highly potent, atypical dopamine receptor ligand — a putative potent full spectrum antipsychotic with low EPS potential

2000 • 18 citations

Switching to aripiprazole monotherapy

2002 • 16 citations

DU 127090: a highly potent, atypical dopamine receptor ligand — high potency but low efficacy at dopamine D2 receptors in vitro

2000 • 12 citations

Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis

2002 • 12 citations

DU 127090: a highly potent, atypical dopamine receptor ligand — pilot study of dopamine D2 receptor occupancy after multiple oral administration of DU 127090 to healthy male volunteers, using 11C-raclopride by means of positron emission tomography

2000 • 8 citations

DU 127090: a highly potent, atypical dopamine receptor ligand — partial agonist character in neurochemistry assays in vivo

2000 • 6 citations

DU 127090: A novel partial dopamine agonist with antipsychotic activity high potency but low efficacy at dopamine D2 receptors in vitro

2003 • 4 citations

DU 127090: A highly potent, atypical dopamine receptor ligand — Behavioral effects of DU 127090 in Cebus non-human primates

2000 • 4 citations